Sign In
Buy STRO
$23.57
-0.160 (-0.674%)
At Close: Jul 17, 2026
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
11:50am, Monday, 26'th Aug 2024
Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
08:00am, Thursday, 22'nd Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
06:45pm, Tuesday, 13'th Aug 2024
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.64 per share a year ago.
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
04:30pm, Tuesday, 13'th Aug 2024
- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the
VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline
10:00am, Monday, 03'rd Jun 2024
CONROE, Texas , June 3, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, a
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
04:30pm, Monday, 13'th May 2024
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 -
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
11:01am, Monday, 13'th May 2024
Sutro Biopharma (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
08:00am, Tuesday, 30'th Apr 2024
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment –
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
06:31pm, Friday, 05'th Apr 2024
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
06:18am, Tuesday, 02'nd Apr 2024
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
01:00am, Tuesday, 02'nd Apr 2024
PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Sutro Biopharma (NASDAQ: STRO, “Sutro”, “the Company”) today announced an exclusive global licensing a
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
07:31pm, Monday, 25'th Mar 2024
Sutro Biopharma, Inc. (STRO) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.82 per share. This compares to loss of $0.61 per share a year ago
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
04:30pm, Monday, 25'th Mar 2024
- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolRα-expressing cancers -
Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now
10:56am, Thursday, 21'st Mar 2024
Sutro Biopharma (STRO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could me
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
05:41am, Wednesday, 28'th Feb 2024
Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
